Adagrasib in Combination With Nab-Sirolimus in Patients Wtih Advanced Solid Tumors and Non-Small Cell Lung Cancer Wtih a KRAS G12C Mutation (KRYSTAL -19)
Not yet recruiting
Aadi Bioscience, Inc.
Phase 1/Phase 2
2023-05-31
This study will evaluate the safety, MTD and/or RP2D, PK, and clinical activity of the
combination of adagrasib with nab-sirolimus in patients with advanced solid tumors/NSCLC with
a KRAS G12C mutation.
Adagrasib in Combination With Nab-Sirolimus in Patients Wtih Advanced Solid Tumors and Non-Small Cell Lung Cancer Wtih a KRAS G12C Mutation (KRYSTAL -19)
Not yet recruiting
Mirati Therapeutics Inc.
Phase 1/Phase 2
2023-05-31
This study will evaluate the safety, MTD and/or RP2D, PK, and clinical activity of the
combination of adagrasib with nab-sirolimus in patients with advanced solid tumors/NSCLC with
a KRAS G12C mutation.
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Recruiting
Mirati Therapeutics Inc.
Phase 2
2023-04-05
This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus
400 mg BID) in patients with NSCLC with KRAS G12C mutation.
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Recruiting
Mirati Therapeutics Inc.
Phase 1
2023-10-18
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess
KO-2806, a farnesyl transferase inhibitor (FTI), as a monotherapy and in combination, in
adult patients with advanced solid tumors.
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Recruiting
Kura Oncology, Inc.
Phase 1
2023-10-18
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess
KO-2806, a farnesyl transferase inhibitor (FTI), as a monotherapy and in combination, in
adult patients with advanced solid tumors.
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
Recruiting
Mirati Therapeutics Inc.
Phase 1
2023-12-28
The purpose of this study is to evaluate the safety and tolerability of INCB099280 in
combination with adagrasib and to establish the MTD or identify RDE(s) for the combination of
INCB099280 and adagrasib.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
